Indications for OCTAPLAS:
Replacement of multiple coagulation factors with acquired deficiencies due to liver disease, undergoing cardiac surgery, or liver transplant. Plasma exchange in thrombotic thrombocytopenic purpura (TTP).
Adults and Children:
For IV infusion only after thawing. Administer based on ABO-blood group compatibility. Coagulation factors replacement: initially 10–15mL/kg to increase plasma coagulation factor levels approx. 15–25%; if hemostasis is not achieved, use higher doses. Adjust based on response; monitor aPTT, PT, and/or specific coagulation factors. TTP: usually 1–1.5 plasma volumes (40–60mL/kg) to completely replace plasma volume removed during plasmapheresis.
IgA deficiency. Severe Protein S deficiency. Prior hypersensitivity to fresh frozen plasma or plasma-derived products including plasma protein.
Risk of transfusion reactions with ABO blood group mismatches. Risk of hypervolemia with high infusion rates; monitor for signs/symptoms of pulmonary edema or cardiac failure. Hyperfibrinolysis may develop due to low levels of alpha2-antiplasmin; monitor for signs of excessive bleeding in liver transplantation. Monitor for thrombosis. Risk of citrate toxicity; use max infusion rate: 0.020–0.025mmol citrate/kg/min (eg, Octaplas <1mL/kg/min). Contains human plasma; monitor for possible infection transmission (eg, viruses, Creutzfeldt-Jakob disease agent). Elderly. Pregnancy. Nursing mothers.
Pooled plasma (human).
Avoid injecting calcium-containing drugs in same IV line. Passive transmission of analytes (eg, β-human chorionic gonadotropin) may cause misleading positive results.
Pruritus, urticaria, nausea, headache, paresthesia; anaphylactic shock, citrate toxicity, severe hypotension.
Generic Drug Availability: